KBKatarzyna Bury

Katarzyna Bury

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katarzyna Bury has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Platinum Nanoparticles as Modulators of Idarubicin Activity: A Physicochemical and In Vitro Biological Study

    by Marcin Zakrzewski, Patrycja Bełdzińska, Karolina Gackowska, Aliaksandra Yurchak, Marzena Jamrógiewicz, Dariusz Wyrzykowski, Katarzyna Bury, Katarzyna Grzyb, Grzegorz Gołuński, Jacek Piosik

    Background/Objectives: Cancer remains one of the leading causes of death worldwide. Although chemotherapy is widely used, it is associated with severe side effects, including myelosuppression and systemic toxicity. Nanoparticles have emerged as promising candidates for modulating drug activity. In this study, we investigated whether platinum nanoparticles (PtNPs) of various sizes interact with idarubicin (IDA), an anthracycline anticancer drug used primarily to treat acute leukaemia. Methods: Interactions between PtNPs and IDA were analysed using dynamic light scattering (DLS), atomic force microscopy (AFM), fluorescence spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, and near-infrared (NIR) spectroscopy. Thermodynamic and thermal properties were assessed using isothermal titration calorimetry (ITC) and differential scanning calorimetry (DSC). Biological effects were evaluated using the Ames mutagenicity assay on the Salmonella enterica serovar Typhimurium TA98 strain and cytotoxicity assays on SK-BR-3 and MCF-7 cell lines. Results: DLS demonstrated changes in the hydrodynamic diameter of PtNPs following IDA addition, which were further supported by AFM imaging. PtNPs significantly quenched IDA fluorescence, indicating close molecular interactions, which were further supported by FTIR and NIR. ITC revealed that the interactions were endothermic, with enthalpy values ranging from 1.2 to 3.6 kcal/mol, and DSC demonstrated that the PtNP-IDA combination altered the melting temperature of IDA. Biological assays revealed that all examined PtNP sizes influenced IDA mutagenicity in the Salmonella enterica serovar Typhimurium TA98 strain. Furthermore, PtNPs modulated the cytotoxicity of IDA in SK-BR-3 and MCF-7 cell lines in a dose-dependent manner. Conclusions: These findings demonstrate that PtNPs interact with IDA and modulate its biological activity. However, in this study no non-cancerous cell lines were examined; therefore, the observed interactions and biological effects support further investigation of the PtNP-IDA combination in the context of nanoparticle-assisted anticancer therapy on a broader range of in vitro cell lines.

  • Open Access

    Building Blocks of 2,3-Diaminopropionic Acid Functionalized with an Oxa-Acid Spacer Shift the Functional Profile of Human Cathelicidin LL-37: Enhanced Enzymatic Stability and Selective Suppression of Neutrophil Degranulation

    by Wiktoria Rejmak, Katarzyna Bury, Marta Bauer, Wojciech Kamysz, Magdalena Wysocka, Adam Lesner

    Background/Objectives: The human cathelicidin LL-37 (37 residues; net charge +6) couples broad-spectrum antimicrobial activity with immunomodulatory function, but rapid proteolysis and peptidylarginine deiminase (PAD)-mediated citrullination limit its therapeutic use. We aimed to enhance enzymatic stability and to test whether substitution with 2,3-diaminopropionic acid (Dap) building blocks bearing an oxa-acid spacer (DAPEG) shifts the functional profile of the LL-37 scaffold. Methods: Six LL-37 analogs were synthesized using Fmoc/tBu solid-phase peptide synthesis, replacing all five arginine, all six lysine, or three isoleucine residues with Dap bearing a one- or two-unit oxa-acid spacer. Identity, purity and secondary structure were assessed via mass spectrometry, ultra-performance liquid chromatography and circular dichroism. Proteolytic stability against human proteinase 3 (PR3), resistance to PAD2/PAD4 citrullination, DNA binding (dynamic light scattering), antibacterial activity, MTT cytotoxicity, and lipopolysaccharide-induced degranulation (PR3 and myeloperoxidase) in differentiated HL-60 cells were evaluated. Results: Proteolytic stability against PR3 increased 5.7-fold for the arginine-substituted Dap(GO1) analog, and both arginine analogs resisted PAD2- and PAD4-mediated citrullination, with Dap(GO2) being the most resistant. DNA binding was qualitatively retained, although dynamic light scattering showed weaker complex compaction for lysine analogs. All six analogs lost direct antibacterial activity and were non-cytotoxic at 1–10 µM. In differentiated HL-60 cells, the lysine-substituted Dap(O1) and Dap(O2) analogs suppressed lipopolysaccharide-induced secretion of both PR3 and myeloperoxidase from azurophilic granules, whereas isoleucine analogs were suppressed partially and arginine analogs behaved like native LL-37. Conclusions: The DAPEG framework shifts LL-37 from microbicidal toward degranulation-suppressive activity, providing a modular route to tune cathelicidin function. The intracellular mechanism (TLR4/FPR2 engagement, cytokine signaling) was not assayed.

  • Open Access

    DAPEG-Modified Analogs of Human Cathelicidin LL-37: Enhanced Proteolytic Stability and Selective Modulation of Neutrophil Degranulation

    by Wiktoria Rejmak, Katarzyna Bury, Marta Bauer, Wojciech Kamysz, Magdalena Wysocka, Adam Lesner

    The human cathelicidin LL-37 (37 amino acids; net charge +6) combines broad-spectrum antimicrobial activity with extensive immunomodulatory function, but its therapeutic exploitation is limited by rapid proteolytic degradation and post-translational inactivation through PAD-mediated citrullination of its arginine residues. We synthesized six analogs of LL-37 in which all five arginine residues (positions 7, 19, 23, 29, 34), all six lysine residues (positions 8, 10, 12, 15, 18, 25) or three isoleucine residues (positions 13, 20, 24) were replaced with the non-proteinogenic amino acid 2,3-diaminopropionic acid (Dap) functionalized on its side chain with either a one- or two-unit oxa-acid spacer (DAPEG building blocks). All compounds were obtained by Fmoc/tBu solid-phase peptide synthesis. Mass spectrometry, UPLC and circular dichroism confirmed identity, purity and partial retention of α-helical secondary structure. Proteolytic stability against human proteinase 3 was 5.7-fold increased for Dap(GO1)[7,19,23,29,34]LL-37 relative to native LL-37; both arginine-substituted analogs showed delayed citrullination by PAD2 and PAD4, with the two-oxa-unit Dap(GO2)[7,19,23,29,34]LL-37 conferring the greatest resistance. All analogs retained DNA binding by qualitative criteria, though DLS revealed reduced complex compaction for lysine-substituted analogs. All six DAPEG analogs lost the direct antibacterial activity of native LL-37 against reference Gram-positive and Gram-negative strains. None of the compounds was cytotoxic at 1–10 µM to HDFa, HB2, HL-60 or differentiated HL-60 cells. In differentiated HL-60 cells the lysine-substituted Dap(O1)[8,10,12,15,18,25]LL-37 and Dap(O2)[8,10,12,15,18,25]LL-37 analogs strongly suppressed LPS-induced secretion of both proteinase 3 and myeloperoxidase from azurophilic primary granules (~37-fold reduction of MPO at 1 h and 23–142-fold reduction at 24 h relative to LL-37 + LPS; all p < 0.001 by Sidak post-hoc) — a concordant two-marker signature of genuine inhibition of neutrophil degranulation. Isoleucine-substituted Dap(MO1)[13,20,24]LL-37 and Dap(MO2)[13,20,24]LL-37 analogs showed significant partial suppression of MPO secretion at both time points (p < 0.001 at 24 h); arginine-substituted analogs exhibited a biphasic phenotype, activating release at 1 h comparably to LL-37 but significantly reducing MPO at 24 h (p < 0.05). The DAPEG framework thus reprofiles the LL-37 scaffold from microbicidal toward selective immunomodulatory function, with the lysine-substituted analogs emerging as the most pharmacologically novel anti-inflammatory candidates.

  • Open Access

    Size dependent impact of platinum nanoparticles on doxorubicin activity

    by Patrycja Bełdzińska, Marcin Zakrzewski, Inez Mruk, Marceli Bogusławski, Natalia Derewońko, Katarzyna Bury, Dariusz Wyrzykowski, Grzegorz Gołuński, Michał Rychłowski, Jacek Piosik


  • Open Access

    Novel Cell Permeable Polymers of N-Substituted L-2,3-Diaminopropionic Acid (DAPEGs) and Cellular Consequences of Their Interactions with Nucleic Acids

    by Anita Romanowska, Katarzyna Węgrzyn, Katarzyna Bury, Emilia Sikorska, Aleksandra Gnatek, Agnieszka Piwkowska, Igor Konieczny, Adam Lesner, Magdalena Wysocka

    The present study aimed to synthesize novel polycationic polymers composed of N-substituted L-2,3-diaminopropionic acid residues (DAPEGs) and investigate their cell permeability, cytotoxicity, and DNA-binding ability. The most efficient cell membrane-penetrating compounds (O2Oc-Dap(GO2)n-O2Oc-NH2, where n = 4, 6, and 8) showed dsDNA binding with a binding constant in the micromolar range (0.3, 3.4, and 0.19 µM, respectively) and were not cytotoxic to HB2 and MDA-MB-231 cells. Selected compounds used in the transfection of a GFP plasmid showed high transfection efficacy and minimal cytotoxicity. Their interaction with plasmid DNA and the increasing length of the main chain of tested compounds strongly influenced the organization and shape of the flower-like nanostructures formed, which were unique for 5/6-FAM-O2Oc-[Dap(GO2)]8-O2Oc-NH2 and typical for large proteins.


  • Open Access

    CLPB (caseinolytic peptidase B homolog), the first mitochondrial protein refoldase associated with human disease

    by Dagmara Mróz, Hubert Wyszkowski, Tomasz Szablewski, Katarzyna Zawieracz, Rafał Dutkiewicz, Katarzyna Bury, Saskia B. Wortmann, Ron A. Wevers, Szymon Ziętkiewicz